Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Regulatory news

Why Invest

Presentations

Media

AIM Rule 26

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

SP Angel Note.pdf

Analyst coverage: SP Angel has released a new research note on N4 Pharma (AIM:N4P), reaffirming their Speculative Buy rating and setting a target price of 2.3p.

The note highlights N4’s proprietary delivery system, Nuvec®, and its growing potential in siRNA and DNA applications. With positive recent data in siRNA delivery, a broadened partner outreach strategy, and a strong balance sheet post-Placing, the company is entering a critical commercialisation phase.

SP Angel sees a clear path to value creation, particularly if partnering discussions progress or additional data further validates Nuvec®'s capabilities.

Read the full analyst note below and don’t forget to submit your questions for the N4 team.

SP Angel - Advancing Nuvec® to commercialisation